City
Epaper

Easy Trip Planners’ board to meet on Jan 24 to consider acquisition proposals

By PNN | Updated: January 20, 2023 12:25 IST

New Delhi (India), January 20: Easy Trip Planners’ board of directors are scheduled to meet on Tuesday, 24th of ...

Open in App

New Delhi (India), January 20: Easy Trip Planners’ board of directors are scheduled to meet on Tuesday, 24th of January, 2023 to consider acquisition proposals. Easy Trip Planners operates the tours and travel service providing platform EaseMyTrip.

Easy Trip Planners, through an exchange filing, informed that its board meeting will meet on January 24, 2023 at 10.00 A.M. to consider the proposals for acquisition. The meeting will be conducted through video conferencing mode, said the regulatory filing.

However, the company has not disclosed about its acquisition plans in the filing but the online travel aggregator EaseMyTrip has been focusing on inorganic acquisitions. It recently acquired Spree Hospitality and YoloBus and will be looking to add two-three more names in the list in FY23.

Easy Trip Planners is looking to acquire companies which have an asset light model and are debt free, along with a positive bottomline. The company management had also clarified that it is aiming for the names which are in the travel space but must be in the non-air segment.

Founded in 2008 by Nishant Pitti, Rikant Pittie, and Prashant Pitti, EaseMyTrip’s online platform enables customers to book air, rail, and bus tickets, hotels, holiday packages, and more. Easy Trip Planners is a bootstrapped venture, which has turned profitable now.

Ease My Trip EPS has shown robust growth since the travel industry recovery post pandemic. The company maintained stable EBIT margins over the last year and business performance has also improved, said Ravi Singhal, CEO, GCL Securities.

“Ease My Trip is now also focusing towards international networking which may further strengthen the business prospects. On technical setup, the stock is showing strength on momentum indicators on the daily chart,” he said.

In November 2022, the company stock went through the corporate action as the company issued bonus shares in 3:1 ratio after the sub-division of each equity share with face value of Rs 2 into two equity shares with a face value of Re 1 each.

Singh added that the oscillators are also suggesting an inherent strength in the counter. Investors may Buy Ease My Trip stock at current levels for the target of Rs 75 putting stop loss of Rs 48-levels.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: EaseMyTripSpree hospitalityNishant pittiRikant pittieindiaNew DelhiThe new delhi municipal councilDelhi south-westIndiUk-indiaRepublic of indiaIndia indiaNew-delhi
Open in App

Related Stories

CricketIND vs PAK 2025 Live Streaming: Head-to-Head Record, When and Where to Watch India vs Pakistan Asia Cup Final

NationalRajnath Singh and Abdeltif Loudiyi Sign MoU on Defence Cooperation; Focus on Counter-Terrorism, Cyber Security, and Maritime Safety (Watch Video)

CricketIND vs PAK 2025 Live Streaming: Head-to-Head Record, When and Where to Watch India vs Pakistan Asia Cup Super 4 Clash

MumbaiNamo Yuva Yatra: Milind Soman Flags Off Campaign in Mumbai, Says ‘Theme of a Drug-Free India Is Very Important’ (Watch Videos)

CricketIND-W vs AUS-W, 3rd ODI: Australia Women Win Toss, Opt to Bat Against India in Series Decider; Check Playing XIs

Business Realted Stories

BusinessGovt appoints new chiefs for Union Bank, Central Bank of India

BusinessWho's Investing in Unlisted Shares--and Why the Retail Crowd is Catching Up

BusinessNext JS Summit India: 2nd Edition Held at Scaler School of Technology, Bengaluru

BusinessBank credit costs likely to decline in H2FY26, near-term slippages to remain elevated: UBS

BusinessHetero Healthcare and Enzene Launch Perzea: Affordable Pertuzumab Biosimilar Expands Breast Cancer Treatment Access in India